Aetna appeal guide
Aetna Saxenda coverage appeal
Aetna uses specific clinical-policy criteria for Saxenda. Most denials come from undocumented BMI history or missing step-therapy notes. Here is how to address both.
Aetna prior authorization criteria for Saxenda
- BMI documentation ≥30 (or ≥27 with weight-related comorbidity)
- 6-month documented lifestyle intervention
- Failure of or contraindication to at least one prior weight-loss medication
- Active monitoring plan with prescriber
Step-by-step appeal flow
- 1
Pull your carrier policy bulletin
Aetna publishes its Saxenda coverage criteria. Read it first — every successful appeal cites it back to the reviewer.
- 2
Document your medical necessity
BMI documentation ≥30 (or ≥27 with weight-related comorbidity) 6-month documented lifestyle intervention Failure of or contraindication to at least one prior weight-loss medication Active monitoring plan with prescriber
- 3
Have your prescriber submit the PA
Most Aetna PAs go through CoverMyMeds or the carrier portal. Your prescriber attaches BMI history, comorbidities (with ICD-10 codes), lifestyle program participation, and prior weight-loss attempts.
- 4
If denied — file the appeal within 60 days
Emphasize medical necessity per Aetna Clinical Policy Bulletin 0794. Cite STEP-1 or SURMOUNT-1 efficacy and the patient's specific comorbidity burden.
- 5
Submit external review if internal appeals fail
After two internal appeals, you can request external review through your state insurance commissioner. ERISA plans go through the federal external-review process.
Letter template
Customizable Aetna appeal letter
We provide a generic medical-necessity letter generator. Customize with the Aetna-specific framing above for highest first-pass success.
Generate appeal letterCommon questions readers ask
- How does Wegovy compare to Saxenda?
- Both are GLP-1 agonists from Novo Nordisk. Wegovy (semaglutide, weekly) produces ~15% mean weight loss; Saxenda (liraglutide, daily) produces ~6-8%. Wegovy is also cheaper per kg-lost, more convenient, and has cardiovascular outcome data (SELECT trial). Saxenda was first approved for adolescents (2020); Wegovy followed in 2022 — both are available for ages 12-17. Full evidence-graded answer
Editorial information based on published Aetna coverage policies as of 2026. Your specific plan benefits may differ — confirm with your insurance card’s member services number. Not legal advice.